Symphogen attracts investors


Copenhagen - Symphogen A/S, a Danish company developing recombinant human polyclonal antibodies for the treatment of several human diseases, has raised Euro20.7 million in a Series D financing round. Participators were existing investors including Essex Woodlands Health Ventures (USA), Scandinavian Life Sciences (SLS) Venture, Novo A/S and Vaekstfonden together with Takeda Research Investment Inc. (TRI). The money is be used to carry out the first stage of clinical trials of Symphogen's lead candidate anti-RhD for the treatment of idiopathic thrombocytopenic purpura (ITP) and hemolytic disease of the newborn (HND).
Since May last year Symphogen has already co-operated for this product (sym001), consisting of 25 distinct antibodies, with the Swedish company Biovitrum AB to produce it according to GMP standards and in sufficient amounts to enter Phase I/II clinical trials.
Now this Danish-Swedish collaboration was expanded: Symphogen has signed a co-development and commercialization agreement with Biovitrum for sym001. Symphogen will receive an initial technology access fee from Biovitrum and milestone payments based on the progress of the programme. The developing costs will be shared equally.



Bagsvaerd/Bangalore – Danish Novozymes A/S has begun a new collaboration with Indian Sea6 Energy. The companies will jointly develop enzymes to convert seaweed-based carbohydrates to sugar, which can then be fermented to produce...



Prague/Turku/Copenhagen – Danish pharmaceutical company H. Lundbeck A/S yesterday unveiled clinical data on its potential blockbuster drug nalmefene at the 2012 European Congress of Psychiatry clinical in Prague. While Lundbeck...



Copenhagen – With the in vitro proof of concept for an undisclosed antibody target, Genmab A/S has reached the second milestone in its collaboration with H. Lundbeck A/S. Genmab will now receive a €1m payment. Under the...



Copenhagen/Bangalore – Biofuels need reliable sources of biomass. Novozymes now looks to the ocean to secure biomass. The Danish enzyme specialist announced an exploratory research agreement with Sea6 Energy from India. The...



Copenhagen – Hellsinn Healthcare has successfully completed a phase Ib trial in Europe with Zealand Pharma’s GLP-2 (glucagone-like peptide 2) peptide antagonist Elsiglutide (ZP1846). The completion of the study, which was...



Copenhagen - An alliance of giants will take a thorough look into biofuels for the maritime sector. The leading enzyme producer Novozymes will team up with parts of the Danish shipping industry, including the world’s largest...



Copenhagen/Paris – Danish biopharma­ceuticals company Zealand Pharma A/S has received some positive news. Ever since French partner Sanofi Aventis submitted a marketing authorisation application for Lyxumia (lixisenatide) in...



Copenhagen/Paris - The cooperation between Danish biopharmaceutical company Zealand Pharma and French drugmaker Sanofi has borne its first fruit. Sanofi has submitted a marketing authorisation application for Lyxumia...



Copenhagen/Ingelheim – Danish HTS expert Nuevolution A/S has signed a license agreement with drugmaker Boeh­ringer Ingelheim (BI). The German pharma company will use Nuevolution’s proprietary Chemetics drug discovery technology...



Bagsværd - Novo Nordisk is investing around €134m in a new corporate centre in the Copenhagen suburb Bagsværd. The new office premises will concentrate the top management and 1,100 administrative employees which are currently...

Displaying results 1 to 10 out of 194

1-10 Next >

© 2007-2015 BIOCOM


All Events


Product of the week


Current issue

All issues